Kornimate/medical-research-clean huggingface dataset:
investigating the cryopreserved blastocyst's implantation potential after genetic screening

Conditions: Infertility; Preimplantation Genetic Screening

Summary: this is a two-arm parallel group randomized controlled trial at the department of reproductive medicine at ghent university hospital. women \>=18 and \<37 years of age undergoing their first or second ivf/icsi treatment, with at least 2 good quality blastocysts remaining after fresh embryo transfer will be randomized to either transfer of a cryopreserved blastocyst selected based on morphology (standard treatment arm) or transfer of a cryopreserved blastocyst selected based on pgs and morphology (intervention treatment arm).


Eligibility criteria:
inclusion criteria: * at least 2 blastocysts suitable for biopsy on day 5 of embryo development remaining after fresh transfer * willing and able to give informed consent * infertility as an indication for ivf/icsi * first or second ivf/icsi cycle * patients willing to accept single embryo transfer * bmi range 18 to 35 kg/m2 exclusion criteria: * any type of genetic abnormality or family history of genetic abnormality in subject or partner * any other non-study related preimplantation genetic testing * three or more clinical miscarriages (recurrent pregnancy loss, rpl) * recurrent implantation failure (rif): no positive β-hcg after transfer (fresh ivf/icsi cycle or frozen) with no less than 6 cleavage stage embryos or no less than 4 blastocysts, all of good quality and of appropriate developmental stage * severe endometriosis * abnormal uterine cavity * cycles requiring surgical sperm recovery procedures, total asthenozoospermia and/or globozoospermia * treatment involving use of donor oocytes or use of gestational carrier
cvd risk reduction trial

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to provide lifestyle counselling for protective health behavior (exercise, diet, smoking cessation) to small groups (6-8 subjects) via teleconference. the sample includes individuals at elevated risk for cardiovascular disease (cvd) as well as individuals with established cvd. our hypothesis is that telephone-based lifestyle counselling will (1) significantly increase protective lifestyle behavior (diet, exercise, smoke-free living) and (2) significantly reduce cvd risk factors at 6-month follow-up.

cohrt was a 2 parallel-group randomized controlled trial that was designed to assess the efficacy of a community outreach strategy for cardiovascular disease (cvd) risk reduction among individuals at elevated risk for cv events. randomization was stratified for diagnosis of chd, type 1 or 2 diabetes, sex, and clinical depression, and blocked within our northern, rural, and urban recruitment sites. a 2x3 mixed factorial design was utilized: 2 groups (usual care, uc/lifestyle counselling,lc) x 3 intervals (baseline, post-treatment, 6-month follow-up). all subjects received personal cvd risk factor feedback and standardized handouts on heart healthy lifestyle change. the lc group received 6 weekly 1-hour sessions of lifestyle counseling that was provided via teleconference in small groups (4-8 persons). group facilitators were trained in a manualized protocol of motivational interviewing that was designed for cvd risk reduction through lifestyle change. weekly supervision was also provided. we hypothesized that the lc group (vs. uc) would significantly increase protective health behavior (exercise, diet, smoke-free living) at post-treatment and 6-month follow-up. the secondary hypothesis was that lc would significantly reduce (1) cvd risk factors, (sbp, dbp, total cholesterol, ldl cholesterol), (2) 10-year absolute risk among subjects without cvd, and (3) significantly increase quality of life as measured by symptoms of depression, psychological stress, and social support.

Eligibility criteria:
inclusion criteria: * 35 to 74 years of age, * diagnosis of cvd or type 1 or 2 diabetes, or * ≥2 of the following cvd risk factors: * confirmed diagnosis of hypertension, * dyslipidemia, * males aged ≥55 years/females aged ≥60 years, * family history of chd or stroke; * current smoker, or * bmi ≥ 27. exclusion criteria: * diagnosis of clinically significant cardiac complications (e.g. arrhythmia, unstable angina) or a congenital cardiac condition; * major psychiatric illness (e.g. psychosis), history of alcohol or drug dependence within the previous year, or residence in a non-private setting.

Keywords: cardiovascular disease prevention lifestyle
all-ceramic crowns in patients with sleep bruxism

Conditions: Sleep Bruxism; Monolithic Ceramic Fixed Dental Prosthesis (Single Crowns)

Summary: the aim of the study is to evaluate the complication rate of 2 types of all-ceramic crowns in patients with or without bruxism.


Eligibility criteria:
inclusion criteria: * need a molar crown * tooth antagonist (no implant) exclusion criteria: * no antagonist pregnancy, bleeding, periodontal diseases
does a nitrofurazone coated bladder catheter reduce the number of urinary tract infections in trauma

Conditions: Trauma; Urinary Tract Infections

Summary: urinary tract infections occurs in trauma. we investigate whether a nitrofurazone coated can reduce the number of urinary tract infections.

urinary tract infection occurs in one in five patients as a complication following severe trauma. a new and approved urinary bladder catheter (releen nf) has been introduced by the danish company coloplast a/s. releen nf is expected to reduce the number of urinary tract infections, but this effect has not been investigated in trauma patients.

Eligibility criteria:
inclusion criteria: * clinical suspicion of multiple trauma * age \>/= 18 years * direct referral from scene of accident * indication for urinary bladder catherization exclusion criteria: * major burn injury * hiv positiv * pregnancy
autologous decidual-like natural killer cells therapy for infertility or adverse pregnancy history

Conditions: Abortion, Habitual; Infertility Unexplained; Embryo Implantation; Pre-Eclampsia

Summary: the aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like nk cells therapy in improving uterine nk cells dysfunction.

menstrual blood analysis will be performed on patients with infertility or a history of adverse pregnancy outcomes who have fertility needs. those with abnormal uterine nk cells function will be screened and given informed consent forms pre-treatment. collecting peripheral blood from the patients, isolating and inducing in vitro culture to obtain autologous decidual like nk cells which will be perfused into their uterine. perform continuous menstrual blood analysis within 6 months after the first treatment to assess the improvement of uterine nk cell function. if the function of uterine nk cells improves, enter the stage of attempting pregnancy and follow up pregnancy outcomes; if the function of uterine nk cells does not improve, then autologous decidual like nk cells uterine cavity perfusion therapy will be performed again. nk cells intrauterine infusion will be treated up to 2 times.

Eligibility criteria:
inclusion criteria: * abnormal uterine nk cell function; * have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two ivf cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction; * have clear fertility desires; * normal ovarian function or with frozen embryos; * edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \>= 7mm; * 18kg/m\^2 \< body mass index \< 30kg/m\^2; exclusion criteria: * using progesterone receptor modulator; * chromosomal karyotype abnormalities in one spouse; * severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium; * uncontrolled autoimmune diseases; * abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study; * history of pelvic malignant tumors; * currently participating in other clinical studies; * allergic to blood products.

Keywords: recurrent pregnancy loss repeated implantation failure unexplained infertility decidual natural killer cells
a study to evaluate the efficacy and safety of alglucosidase alfa produced at the 4000 l scale for pompe disease

Conditions: Pompe Disease

Summary: the objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (l) alglucosidase alfa (lumizyme®) in pompe participants.


Eligibility criteria:
inclusion criteria: a participant might meet all of the following criteria to be eligible for this study. 1. the participant and/or their parent/legal guardian was willing and able to provide signed informed consent. 2. the participant might be at least 1 year of age at the time of informed consent. 3. the participant had a diagnosis of pompe disease and might have received treatment with 160 l alglucosidase alfa prior to screening. 4. the participant, if female and of childbearing potential, might have a negative pregnancy test (urine beta-human chorionic gonadotropin) at baseline. note: all female participants of childbearing potential and sexually mature males might agree to use a medically accepted method of contraception throughout the study. exclusion criteria: a participant who met any of the following criteria were to be excluded from this study. 1. the participant had within the past 3 months received or was currently receiving any investigational product other than 160 l alglucosidase alfa or was currently participating in another clinical treatment study. 2. the participant, in the opinion of the investigator, was clinically unstable and would not be expected to survive to completion of the 52-week treatment period. 3. the participant and/or their parent/legal guardian, in the opinion of the investigator, was unable to adhere to the requirements of the study.
safety, tolerability and efficacy study of abt-089 in adults with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention-Deficit/Hyperactivity Disorder

Summary: the purpose of this study is to test if the investigational medication abt-089 is a safe and effective treatment for adults with attention-deficit/hyperactivity disorder (adhd).


Eligibility criteria:
inclusion criteria: * have voluntarily signed an informed consent form. * meet diagnostic criteria for attention-deficit/hyperactivity disorder (adhd) based on detailed evaluation and interview with subject. * subject is generally in good health based on medical history, physical examination, clinical lab tests and ecg. * female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. * male subjects must agree to comply with applicable contraceptive requirements. * subject is able to keep required appointments for clinic visits and all tests, including blood draws and examinations. exclusion criteria: * subject has a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder. * current diagnosis of major depressive disorder, generalized anxiety disorder, ptsd or has a sleep disorder requiring treatment of any kind. * subject has a history of, or ongoing, serious medical problem. * subject has a history of significant allergic reaction to any drug. * subject is planning to begin any type of behavioral or psychotherapy for treatment of adhd. * subject requires ongoing treatment with any psychiatric medication.
the analysis of bmi, asthma prevalence, and lung functions of schoolchildren in southern taiwan

Conditions: Asthma; Obesity

Summary: the prevalence of obesity and asthma has increased in recent decades. we investigated the relationship between body mass index (bmi) and lung function, and also tried to determine if asthma prevalence differs between obese and non-obese children. we propose this cross-sectional, retrospective analysis to figure out whether the bmi is associated with elevated prevalence of asthma, and how their lung function changes in different bmi groups.


Eligibility criteria:
inclusion criteria: * students representing all grades in a total of 123 junior high schools in southern taiwan (kaohsiung and pintong) between 1995-1996 exclusion criteria: * failure to obtain isaac questionnaire * failure to preform lung functions study

Keywords: asthma pulmonary function tests obesity
effect of branched-chain amino acids (bcaa) to muscle cramps in patients with cirrhosis

Conditions: Muscle Cramp; Cirrhosis; Quality of Life

Summary: the goal of this randomized controlled trial is to compare the efficacy and safety of branched-chain amino acids (bcaa) versus placebo for treating muscle cramps in cirrhotic patients. the main questions it aims to answer are: * compared the effect of bcaa versus placebo on muscle cramp frequency in cirrhotic patients * compared the effect of bcaa versus placebo on muscle cramp duration and severity in cirrhotic patients * compared the effect of bcaa versus placebo on quality of life in cirrhotic patients with muscle cramps participants with cirrhosis who have experienced muscle cramps at least once per week will be randomized to receive either a placebo or 12.45 grams of bcaa orally per day for 12 weeks.

cirrhosis is a late-stage of fibrosis of the liver caused by many forms of liver disease. muscle cramps are visible or palpable involuntary contraction part of the muscle. the prevalence of cramps in cirrhosis varied range from 31-78%. the pathophysiology of cramps in cirrhosis was explained by multiple mechanisms such as energy metabolism, nerve function, and plasma volume. cramps significantly diminished the quality of life in cirrhotic patients. many drugs, vitamins, and minerals were studied for treating cramps in cirrhosis in previous studies but no clinical improvement, good randomized control studies, or side effects. branched-chain amino acids (bcaa) had been developed to correct this amino acid imbalance and helped to decrease the frequency of cramps and improve the quality of life in cirrhotic patients from previous studies but there were no control groups and a small number of patients were included. the aim of this study was to evaluate the efficacy and safety of bcaa for controlling muscle cramps in cirrhotic patients.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * muscle cramp ≥ 1 time per week * confirmed cirrhotic status (radiologic finding compatible with cirrhosis or liver stiffness measurement ≥ 12.5 kpa by transient elastography method or pathological confirm of cirrhosis) exclusion criteria: * allergy to bcaa * overt hepatic encephalopathy * hepatorenal syndrome * severe renal insufficiency; egfr \< 30 * heart failure * peripheral arterial disease * active malignancies beyond hepatocellular carcinoma * heavy alcohol drinking (\> 21g/day for men and \>14g/day for women) * pregnancy or lactation * current use of bcaa within 3 months * recent adding or titrating diuretics within 4 weeks * on current medications for muscle cramp relief such as vitamin e, taurine, carnitine, narcotic pain medications, baclofen, methocarbamol, other muscle relaxers, nsaids, or other antispastic agents.

Keywords: muscle cramp cirrhosis
study evaluating isovorin in colon cancer

Conditions: Colon Cancer

Summary: the purpose of the study is to verify superiority of 1-lv/5fu therapy to uft therapy of relapse-free survival time in patients with dukes c and cure a colon cancer. secondary endpoints include disease-free survival time, survival time, and safety.


Eligibility criteria:
inclusion criteria: * dukes c, cure a colon cancer diagnosed histologically or cytologically * normal organ function of bone marrow, heart, liver and kidney * age 20-75 other inclusion applies exclusion criteria: * serious bone marrow suppression, infection, heart disease or complication * familial adenomatous polyposis or hereditary nonpolyposis * pregnant or breastfeeding women other exclusion applies

Keywords: colon cancer
a registry of tuberculosis cases in the cpcra

Conditions: HIV Infections; Tuberculosis

Summary: primary: to estimate the proportion of tuberculosis patients in the cpcra who have drug-resistant tuberculosis (tb) and to describe the patterns of drug resistance. secondary: to compare drug resistance data on the mycobacterium tuberculosis isolates of hiv-infected patients to those of hiv-uninfected patients who are being followed in the cpcra. to assess the relationship of resistance data with geographic, demographic, and hiv and tb risk factor information. geographic areas and demographic subgroups affected by the tb epidemic appear to be congruent and associated with the concurrent hiv epidemic. the total number of cpcra patients who will develop, or who have experienced, confirmed tb is unknown. it is critical to determine the depth and breadth of the current problem of drug-resistant tb.

geographic areas and demographic subgroups affected by the tb epidemic appear to be congruent and associated with the concurrent hiv epidemic. the total number of cpcra patients who will develop, or who have experienced, confirmed tb is unknown. it is critical to determine the depth and breadth of the current problem of drug-resistant tb. for both retrospective and prospective components of the study, demographic, geographic, hiv and tb risk factor information will be collected on cpcra patients with confirmed pulmonary or extrapulmonary tb. mycobacterial culture results will be recorded. retrospective data will be collected on cpcra patients with confirmed tuberculosis who have been diagnosed since january 1992 until the time of site registration. prospective data will be collected on cpcra patients with confirmed tuberculosis diagnosed during the period of 1 to 2 years following site registration.

Eligibility criteria:
patients must meet the following criteria: * cpcra patients with confirmed pulmonary or extrapulmonary tb. confirmed clinical tb requires a positive culture for mycobacterium tuberculosis. note: * there is no requirement that patients have hiv infection.

Keywords: tuberculosis mycobacterium tuberculosis aids-related opportunistic infections acquired immunodeficiency syndrome drug resistance, microbial
preheating of femur component in hybrid total hip arthroplasty

Conditions: Osteoarthritis, Hip

Summary: background * recently published studies confirm that preheating of femoral component enhances shear strength of implant-cement interface. both iesaka et al 2003 and jafri et al 2004 showed reduction in cement porosity on cement-implant interface with preheated femur components. we will use the radiostereometry analysis (rsa) to investigate how the preheating of femur component influence on prosthesis survivorship. there are no clinical controlled studies performed to the date. the aim of the study * comparison of the migration rates between preheated and non-preheated femur components, analyzed with rsa. methods * randomization of 80 patients into 2 groups with 40 in each. all patients will undergo standard hybrid total hip replacement. in group one the femur component (bi-metric, interlock biomet) will be preheated to 40 degrees of celsius before cementation. in group two: the control group, the femur component will be of room temperature. we will measure the temperature at cement bone interface during the operation with use of thermocouple electrodes inserted through separate drill hole in the femur. the measurements will be recorded every 10 seconds. the patients will follow the standard postoperative rehabilitation program. * the rsa analysis will be performed the first day after the operation and at 3, 12, 24 months postoperatively. * the dual-energy x-ray absorptiometry scanning (dexa) of the femur will be performed at the first week after the operation and at 12 and 24 months postoperatively. * the patients will be followed both clinically and radiologically at 1 and 2 years after the operation (harris hip score). * the results will be expressed as mean + sd (in mm). anova statistical analysis will be used to confirm the differences between the groups.


Eligibility criteria:
inclusion criteria: * the patients suffering of hip osteoarthritis exclusion criteria: * the patients with asa score \>ii * the patients with cancer * the secondary coxarthrosis after the trauma * any vascular or neuromuscular diseases affecting the hip.

Keywords: arthroplasty, hip, pre-heating, radiostereometric analysis, dual-energy radiographic absorptiometry,
the origin of infrapyloric artery

Conditions: Stomach Neoplasm

Summary: infrapyloric artery(ipa) is of great importance for gastric cancer patients. according to previous study, the origin of ipa varies greatly among different studies. this trial aims to tell the distribution of ipa origin in chinese patients.

infrapyloric artery(ipa) is of great importance for gastric cancer patients. in early gastric cancer patients, the pylorus-preserving gastrectomy requires the preserving of ipa. in advanced gastric cancer patients, the subgroup of no. 6 lymph node might be associated with ipa. in japanese gastric cancer association(jgca) gastric cancer classification guidelines, the no. 6 lymph nodes is defined as lymph nodes along the first branch and proximal part of the right gastroepiploic artery(rgea) down to the confluence of the right gastroepiploic vein and the anterior superior pancreatoduodenal vein. however,if ipa origins from the gastroduodenal artery(gda) or anterior superior pancreatoduodenal artery(aspda), the lymph nodes along the ipa can not be grouped into the no. 6 lymph nodes. thus, a new definition of no. 6 lymph nodes is needed on the basis of the origin of ipa. previous studies about ipa origin are few and the origin of ipa varies greatly among different studies.

Eligibility criteria:
inclusion criteria: * patients with gastric cancer who needs to receive total or distal gastrectomy. * signed informed consent exclusion criteria: * ipa not dissected, photo-taken or video-recorded.

Keywords: infrapyloric artery gastric cancer